Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
7 "Jang Ho Cho"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
General
Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations
Yoon Ji Choi, Jung Yoon Choi, Ju Won Kim, Ah Reum Lim, Youngwoo Lee, Won Jin Chang, Soohyeon Lee, Jae Sook Sung, Hee-Joon Chung, Jong Won Lee, Eun Joo Kang, Jung Sun Kim, Taekyu Lim, Hye Sook Kim, Yu Jung Kim, Mi Sun Ahn, Young Saing Kim, Ji Hyun Park, Seungtaek Lim, Sung Shim Cho, Jang Ho Cho, Sang Won Shin, Kyong Hwa Park, Yeul Hong Kim
Cancer Res Treat. 2022;54(1):30-39.   Published online May 20, 2021
DOI: https://doi.org/10.4143/crt.2021.218
AbstractAbstract PDFPubReaderePub
Purpose
K-MASTER project is a Korean national precision medicine platform that screened actionable mutations by analyzing next-generation sequencing (NGS) of solid tumor patients. We compared gene analyses between NGS panel from the K-MASTER project and orthogonal methods.
Materials and Methods
Colorectal, breast, non–small cell lung, and gastric cancer patients were included. We compared NGS results from K-MASTER projects with those of non-NGS orthogonal methods (KRAS, NRAS, and BRAF mutations in colorectal cancer [CRC]; epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK] fusion, and reactive oxygen species 1 [ROS1] fusion in non–small cell lung cancer [NSCLC], and Erb-B2 receptor tyrosine kinase 2 (ERBB2) positivity in breast and gastric cancers).
Results
In the CRC cohort (n=225), the sensitivity and specificity of NGS were 87.4% and 79.3% (KRAS); 88.9% and 98.9% (NRAS); and 77.8% and 100.0% (BRAF), respectively. In the NSCLC cohort (n=109), the sensitivity and specificity of NGS for EGFR were 86.2% and 97.5%, respectively. The concordance rate for ALK fusion was 100%, but ROS1 fusion was positive in only one of three cases that were positive in orthogonal tests. In the breast cancer cohort (n=260), ERBB2 amplification was detected in 45 by NGS. Compared with orthogonal methods that integrated immunohistochemistry and in situ hybridization, sensitivity and specificity were 53.7% and 99.4%, respectively. In the gastric cancer cohort (n=64), ERBB2 amplification was detected in six by NGS. Compared with orthogonal methods, sensitivity and specificity were 62.5% and 98.2%, respectively.
Conclusion
The results of the K-MASTER NGS panel and orthogonal methods showed a different degree of agreement for each genetic alteration, but generally showed a high agreement rate.

Citations

Citations to this article as recorded by  
  • Genomic Profiling of Driver Gene Alterations in Patients With Non–Small Cell Lung Cancer, Patterns of Treatment and Impact on Survival Outcomes: A Single Center Experience of More Than 1200 Patients
    Minit Shah, Vanita Noronha, Vijay Patil, Ajay Kumar Singh, Nandini Menon, Supriya Goud, Srushti Shah, Sucheta More, Akhil Kapoor, Bal Krishna Mishra, Pratik Chandrani, Anuradha Chougule, Vinod Gupta, Priyanka Pange, Omshree Shetty, Trupti Pai, Rajiv Kaush
    Clinical Lung Cancer.2025;[Epub]     CrossRef
  • Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer
    Yonghwa Choi, Jangwoo Lee, Keewon Shin, Ji Won Lee, Ju Won Kim, Soohyeon Lee, Yoon Ji Choi, Kyong Hwa Park, Jwa Hoon Kim
    BMC Cancer.2024;[Epub]     CrossRef
  • Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator
    Albrecht Stenzinger, Brian Cuffel, Noman Paracha, Eric Vail, Jesus Garcia-Foncillas, Clifford Goodman, Ulrik Lassen, Gilles Vassal, Sean D Sullivan
    The Oncologist.2023; 28(5): e242.     CrossRef
  • Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer
    Kyoungmin Lee, Jongwon Lee, Jungmin Choi, Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee-Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, In Hae Park
    Scientific Reports.2023;[Epub]     CrossRef
  • Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
    Shinkyo Yoon, Miso Kim, Yong Sang Hong, Han Sang Kim, Seung Tae Kim, Jihun Kim, Hongseok Yun, Changhoon Yoo, Hee Kyung Ahn, Hyo Song Kim, In Hee Lee, In-Ho Kim, Inkeun Park, Jae Ho Jeong, Jaekyung Cheon, Jin Won Kim, Jina Yun, Sun Min Lim, Yongjun Cha, Se
    Cancer Research and Treatment.2022; 54(1): 1.     CrossRef
  • 8,909 View
  • 263 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance
Hee Kyung Kim, Kyung Hee Park, Youjin Kim, Song Ee Park, Han Sang Lee, Sung Won Lim, Jang Ho Cho, Ji-Yeon Kim, Jeong Eon Lee, Jin Seok Ahn, Young-Hyuck Im, Jong Han Yu, Yeon Hee Park
Cancer Res Treat. 2019;51(2):737-747.   Published online September 5, 2018
DOI: https://doi.org/10.4143/crt.2018.342
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We aimed to analyze the discordance between immunohistochemistry (IHC)-based surrogate subtyping and PAM50 intrinsic subtypes and to assess overall survival (OS) according to discordance.
Materials and Methods
A total of 607 patients were analyzed. Hormone receptor (HR) expression was evaluated by IHC, and human epidermal growth factor receptor 2 (HER2) expression was analyzed by IHC and/or fluorescence in situ hybridization. PAM50 intrinsic subtypes were determined according to 50 cancer genes using the NanoString nCounter Analysis System. We matched concordant tumor as luminal A and HR+/HER2–, luminal B and HR+/HER2+, HR–/HER2+ and HER2–enriched, and triple-negative breast cancer (TNBC) and normal- or basal-like. We used Ion Ampliseq Cancer Panel v2 was used to identify the genomic alteration related with discordance. The Kaplan-Meier method was used to estimate OS.
Results
In total, 233 patients (38.4%) were discordant between IHC-based subtype and PAM50 intrinsic subtype. Using targeted sequencing, we detected somatic mutation–related discordant breast cancer including the VHL gene in the HR+/HER2– group (31% in concordant group, 0% in discordant group, p=0.03) and the IDH and RET genes (7% vs. 12%, p=0.02 and 0% vs. 25%, p=0.02, respectively) in the TNBC group. Among the luminal A/B patients with a discordant result had significantly worse OS (median OS, 73.6 months vs. not reached; p < 0.001), and among the patients with HR positivity, the basal-like group as determined by PAM50 showed significantly inferior OS compared to other intrinsic subtypes (5-year OS rate, 92.2% vs. 75.6%; p=0.01).
Conclusion
A substantial portion of patients showed discrepancy between IHC subtype and PAM50 intrinsic subtype in our study. The survival analysis demonstrated that current IHC-based classification could mislead the treatment and result in poor outcome. Current guidelines for IHC might be updated accordingly.

Citations

Citations to this article as recorded by  
  • Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer
    Brenno Pastò, Riccardo Vida, Arianna Dri, Lorenzo Foffano, Serena Della Rossa, Lorenzo Gerratana, Fabio Puglisi
    The Breast.2025; 79: 103859.     CrossRef
  • Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
    Florencia P. Madorsky Rowdo, Rachel Martini, Sarah E. Ackermann, Colin P. Tang, Marvel Tranquille, Adriana Irizarry, Ilkay Us, Omar Alawa, Jenna E. Moyer, Michael Sigouros, John Nguyen, Majd Al Assaad, Esther Cheng, Paula S. Ginter, Jyothi Manohar, Brian
    Cancer Research.2025; 85(3): 551.     CrossRef
  • Defining the regulatory logic of breast cancer using single-cell epigenetic and transcriptome profiling
    Matthew J. Regner, Susana Garcia-Recio, Aatish Thennavan, Kamila Wisniewska, Raul Mendez-Giraldez, Brooke Felsheim, Philip M. Spanheimer, Joel S. Parker, Charles M. Perou, Hector L. Franco
    Cell Genomics.2025; 5(2): 100765.     CrossRef
  • Evaluation and Comparison of Prognostic Multigene Tests in Early‐Stage Breast Cancer: Which Is the Most Effective? A Literature Review Exploring Clinical Utility to Enhance Therapeutic Management in Luminal Patients
    Marianna Rita Brogna, Gerardo Ferrara, Valeria Varone, Angela Montone, MariaRosaria Schiano, Michele DelSesto, Francesca Collina
    Molecular Carcinogenesis.2025;[Epub]     CrossRef
  • Imaging genomics of cancer: a bibliometric analysis and review
    Xinyi Gou, Aobo Feng, Caizhen Feng, Jin Cheng, Nan Hong
    Cancer Imaging.2025;[Epub]     CrossRef
  • PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study
    Judith Katharina Ballé, Martina Vetter, Tariku Wakuma Kenea, Pia Eber-Schulz, Christian Reibold, Hannes-Viktor Ziegenhorn, Kathrin Stückrath, Claudia Wickenhauser, Adamu Addissie, Pablo Santos, Eva Johanna Kantelhardt, Sefonias Getachew, Marcus Bauer
    BMC Cancer.2024;[Epub]     CrossRef
  • Migratory Tumor Cells Cooperate with Cancer Associated Fibroblasts in Hormone Receptor-Positive and HER2-Negative Breast Cancer
    Eun Hye Joo, Sangmin Kim, Donghyun Park, Taeseob Lee, Woong-Yang Park, Kyung Yeon Han, Jeong Eon Lee
    International Journal of Molecular Sciences.2024; 25(11): 5876.     CrossRef
  • Discovery of a proliferation essential gene signature and actin‐like 6A as potential biomarkers for predicting prognosis and neoadjuvant chemotherapy response in triple‐positive breast cancer
    Xiaofen Li, Shiping Luo, Wenfen Fu, Mingyao Huang, Xiewei Huang, Shaohong Kang, Jie Zhang, Qingshui Wang, Chuangui Song
    Cancer.2024; 130(S8): 1435.     CrossRef
  • Breast Cancer Molecular Subtyping in Practice: A Real-World Study of the APIS Breast Cancer Subtyping Assay in a Consecutive Series of Breast Core Biopsies
    Silvana Di Palma, Panagiotis Koliou, Alex Simonovic, Daniela Costa, Catherine Faulkes, Brenda Kobutungi, Felicity Paterson, Jonathan David Horsnell, Farrokh Pakzad, Tracey Irvine, Polly Partlett, Elizabeth Clayton, Nadine Collins
    International Journal of Molecular Sciences.2024; 25(5): 2616.     CrossRef
  • iCluF: an unsupervised iterative cluster-fusion method for patient stratification using multiomics data
    Sushil K Shakyawar, Balasrinivasa R Sajja, Jai Chand Patel, Chittibabu Guda, Marieke Kuijjer
    Bioinformatics Advances.2024;[Epub]     CrossRef
  • Differences in Histological Subtypes of Invasive Lobular Breast Carcinoma According to Immunohistochemical Molecular Classification
    Ivan Ilić, Jana Cvetković, Ratko Ilić, Ljubiša Cvetković, Aleksandar Milićević, Stefan Todorović, Pavle Ranđelović
    Diagnostics.2024; 14(6): 660.     CrossRef
  • Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study
    Tobias Berg, Maj-Britt Jensen, Alan Celik, Maj-Lis Talman, Maria Anna Misiakou, Ann Søegaard Knoop, Finn Cilius Nielsen, Bent Ejlertsen, Maria Rossing
    JCI Insight.2024;[Epub]     CrossRef
  • Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review
    Katerina S. Grechukhina, Daria A. Filonenko, Margarita V. Sukhova, Liudmila G. Zhukova
    Journal of Modern Oncology.2024; 26(2): 182.     CrossRef
  • Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study
    Ran Ran, Shidi Zhao, Yan Zhou, Xinyue Hang, Hui Wang, Yuan Fan, Yusi Zhang, Yifan Qiao, Jin Yang, Danfeng Dong
    BMC Cancer.2024;[Epub]     CrossRef
  • LUCAT1-Mediated Competing Endogenous RNA (ceRNA) Network in Triple-Negative Breast Cancer
    Deepak Verma, Sumit Siddharth, Ashutosh S. Yende, Qitong Wu, Dipali Sharma
    Cells.2024; 13(22): 1918.     CrossRef
  • Systemically Identifying Triple-Negative Breast Cancer Subtype-Specific Prognosis Signatures, Based on Single-Cell RNA-Seq Data
    Kaiyuan Xing, Bo Zhang, Zixuan Wang, Yanru Zhang, Tengyue Chai, Jingkai Geng, Xuexue Qin, Xi Steven Chen, Xinxin Zhang, Chaohan Xu
    Cells.2023; 12(3): 367.     CrossRef
  • Moanna: Multi-Omics Autoencoder-Based Neural Network Algorithm for Predicting Breast Cancer Subtypes
    Richard Lupat, Rashindrie Perera, Sherene Loi, Jason Li
    IEEE Access.2023; 11: 10912.     CrossRef
  • Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer
    Thérèse Dix-Peek, Boitumelo P. Phakathi, Eunice J. van den Berg, Caroline Dickens, Tanya N. Augustine, Herbert Cubasch, Alfred I. Neugut, Judith S. Jacobson, Maureen Joffe, Paul Ruff, Raquel A. B. Duarte
    Breast Cancer Research and Treatment.2023; 199(1): 1.     CrossRef
  • A Simple Method for Robust and Accurate Intrinsic Subtyping of Breast Cancer
    Mehdi Hamaneh, Yi-Kuo Yu
    Cancer Informatics.2023;[Epub]     CrossRef
  • XAI-MethylMarker: Explainable AI approach for biomarker discovery for breast cancer subtype classification using methylation data
    Sheetal Rajpal, Ankit Rajpal, Arpita Saggar, Ashok K. Vaid, Virendra Kumar, Manoj Agarwal, Naveen Kumar
    Expert Systems with Applications.2023; 225: 120130.     CrossRef
  • XAI-CNVMarker: Explainable AI-based copy number variant biomarker discovery for breast cancer subtypes
    Sheetal Rajpal, Ankit Rajpal, Manoj Agarwal, Virendra Kumar, Ajith Abraham, Divya Khanna, Naveen Kumar
    Biomedical Signal Processing and Control.2023; 84: 104979.     CrossRef
  • The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity
    Vincenzo Salemme, Giorgia Centonze, Lidia Avalle, Dora Natalini, Alessio Piccolantonio, Pietro Arina, Alessandro Morellato, Ugo Ala, Daniela Taverna, Emilia Turco, Paola Defilippi
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
    Coralia Bueno Muiño, Miguel Martín, María del Monte-Millán, José Ángel García-Saénz, Sara López-Tarruella
    Cancers.2022; 14(3): 512.     CrossRef
  • Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
    Fanfan Li, Qian Ju, Cong Gao, Jingjing Li, Xiaolei Wang, Min Yan, Liying Zhang, Meiling Huang, Qihe Long, Xiangting Jin, Nanlin Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer
    Xinyu Ren, Yu Song, Yanna zhang, Huanwen Wu, Longyun Chen, Junyi Pang, Liangrui Zhou, Songjie Shen, Zhiyong Liang
    BMC Cancer.2022;[Epub]     CrossRef
  • Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting
    Ramona Erber, Miriam Angeloni, Robert Stöhr, Michael P. Lux, Daniel Ulbrich-Gebauer, Enrico Pelz, Agnes Bankfalvi, Kurt W. Schmid, Robert F. H. Walter, Martina Vetter, Christoph Thomssen, Doris Mayr, Frederick Klauschen, Peter Sinn, Karl Sotlar, Katharina
    International Journal of Molecular Sciences.2022; 23(15): 8716.     CrossRef
  • The Current Staging and Classification Systems of Breast Cancer and Their Pitfalls: Is It Possible to Integrate the Complexity of this Neoplasm into a Unified Staging System?
    Felipe Andrés Cordero da Luz, Breno Jeha Araújo, Rogério Agenor de Araújo
    Critical Reviews in Oncology/Hematology.2022; : 103781.     CrossRef
  • Prognostic factors and molecular subtypes in young women with breast cancer
    Yasmin Shukair, Rafaela Veiga Monteiro
    Mastology.2022;[Epub]     CrossRef
  • Understanding Breast Cancers through Spatial and High-Resolution Visualization Using Imaging Technologies
    Haruko Takahashi, Daisuke Kawahara, Yutaka Kikuchi
    Cancers.2022; 14(17): 4080.     CrossRef
  • Risk Stratification for Breast Cancer Patient by Simultaneous Learning of Molecular Subtype and Survival Outcome Using Genetic Algorithm-Based Gene Set Selection
    Bonil Koo, Dohoon Lee, Sangseon Lee, Inyoung Sung, Sun Kim, Sunho Lee
    Cancers.2022; 14(17): 4120.     CrossRef
  • Detecting the expression of HRs and BCL2 via IHC can help identify luminal A-like subtypes of triple-positive breast cancers
    Yingying Xu, Yonghao Liang, Guanghao Yin
    Clinical and Translational Oncology.2022; 25(4): 1024.     CrossRef
  • Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
    Marcela Carausu, Matthieu Carton, Véronique Diéras, Thierry Petit, Séverine Guiu, Anthony Gonçalves, Paule Augereau, Jean Marc Ferrero, Christelle Levy, Mony Ung, Isabelle Desmoulins, Marc Debled, Thomas Bachelot, Barbara Pistilli, Jean-Sébastien Frenel,
    JAMA Network Open.2022; 5(12): e2247154.     CrossRef
  • Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review
    Ran Ran, Yingying Ma, Hui Wang, Jin Yang, Jiao Yang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study
    Lin Wang, Qian Li, Vasily N. Aushev, Alfred I. Neugut, Regina M. Santella, Susan Teitelbaum, Jia Chen
    Breast Cancer.2021; 28(6): 1235.     CrossRef
  • Triphasic DeepBRCA-A Deep Learning-Based Framework for Identification of Biomarkers for Breast Cancer Stratification
    Sheetal Rajpal, Manoj Agarwal, Virendra Kumar, Anamika Gupta, Naveen Kumar
    IEEE Access.2021; 9: 103347.     CrossRef
  • Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level
    Yan Zhang, Denan Zhang, Qingkang Meng, Ziqi Liu, Hongbo Xie, Lei Liu, Fei Xu, Xiujie Chen
    BMC Cancer.2021;[Epub]     CrossRef
  • A single-cell and spatially resolved atlas of human breast cancers
    Sunny Z. Wu, Ghamdan Al-Eryani, Daniel Lee Roden, Simon Junankar, Kate Harvey, Alma Andersson, Aatish Thennavan, Chenfei Wang, James R. Torpy, Nenad Bartonicek, Taopeng Wang, Ludvig Larsson, Dominik Kaczorowski, Neil I. Weisenfeld, Cedric R. Uytingco, Jen
    Nature Genetics.2021; 53(9): 1334.     CrossRef
  • Improving Prognosis of Surrogate Assay for Breast Cancer Patients by Absolute Quantitation of Ki67 Protein Levels Using Quantitative Dot Blot (QDB) Method
    Junmei Hao, Yan Lyu, Jiarui Zou, Yunyun Zhang, Shuishan Xie, Lili Jing, Fangrong Tang, Jiahong Lyu, Wenfeng Zhang, Jianbo Zhang, Xunting Wang, Kuisheng Chen, Jiandi Zhang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Poor histologic tumor response after adjuvant therapy in basal-like HER2-positive breast carcinoma
    Danhui Zhao, Xin Fu, Joseph Rohr, Yingmei Wang, Mingyang Li, Xiuming Zhang, Junhui Qin, Mengwei Xu, Chao Li, Guorui Sun, Zhe Wang, Shuangping Guo
    Pathology - Research and Practice.2021; 228: 153677.     CrossRef
  • Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets
    Stefania Morganti, Giuseppe Curigliano
    Expert Review of Precision Medicine and Drug Development.2020; 5(1): 7.     CrossRef
  • MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes
    Elise Klæstad, Signe Opdahl, Monica Jernberg Engstrøm, Borgny Ytterhus, Elisabeth Wik, Anna Mary Bofin, Marit Valla
    Breast Cancer Research and Treatment.2020; 180(1): 73.     CrossRef
  • Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Liuwen Yu, Fangmeng Fu, Jing Li, Meng Huang, Bangwei Zeng, Yuxiang Lin, Qian Mei, Jinxing Lv, Chuan Wang
    Journal of Oncology.2020; 2020: 1.     CrossRef
  • Hormone Receptor-Status Prediction in Breast Cancer Using Gene Expression Profiles and Their Macroscopic Landscape
    Seokhyun Yoon, Hye Sung Won, Keunsoo Kang, Kexin Qiu, Woong June Park, Yoon Ho Ko
    Cancers.2020; 12(5): 1165.     CrossRef
  • Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?
    Jing Yu, Jiayi Wu, Ou Huang, Jianrong He, Zhu Li, Weiguo Chen, Yafen Li, Xiaosong Chen, Kunwei Shen
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • DGM-CM6: A New Model to Predict Distant Recurrence Risk in Operable Endocrine-Responsive Breast Cancer
    Lei Lei, Xiao-Jia Wang, Yin-Yuan Mo, Skye Hung-Chun Cheng, Yunyun Zhou
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Subtype-specific risk models for accurately predicting the prognosis of breast cancer using differentially expressed autophagy-related genes
    Baoai Han, He Zhang, Yuying Zhu, Xingxing Han, Zhiyong Wang, Zicong Gao, Yue Yuan, Ruinan Tian, Fei Zhang, Ruifang Niu
    Aging.2020; 12(13): 13318.     CrossRef
  • Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
    Ji-Yeon Kim, Kyunghee Park, Seock-Ah Im, Kyung Hae Jung, Joohyuk Sohn, Keun Seok Lee, Jee Hyun Kim, Yaewon Yang, Yeon Hee Park
    Breast Cancer Research and Treatment.2020; 184(3): 743.     CrossRef
  • Quantification of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Protein Expression in Bone Biopsies by Targeted Mass Spectrometry without Acid Decalcification
    Regine M Schoenherr, Uliana J Voytovich, Jeffrey R Whiteaker, Vijayakrishna K Gadi, Julie R Gralow, Amanda G Paulovich
    Clinical Chemistry.2020; 66(11): 1459.     CrossRef
  • A Topic Modeling Analysis of TCGA Breast and Lung Cancer Transcriptomic Data
    Filippo Valle, Matteo Osella, Michele Caselle
    Cancers.2020; 12(12): 3799.     CrossRef
  • Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease
    Giuseppe Viale, Elisabetta Munzone
    The Breast.2019; 48: S49.     CrossRef
  • 13,849 View
  • 483 Download
  • 53 Web of Science
  • 50 Crossref
Close layer
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Seonggyu Byeon, Youjin Kim, Sung Won Lim, Jang Ho Cho, Sehoon Park, Jiyun Lee, Jong-Mu Sun, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):623-631.   Published online July 23, 2018
DOI: https://doi.org/10.4143/crt.2018.151
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for approximately 4% of all EGFR mutations. Given the rarity of this mutation, its clinical outcomes are not fully established.
Materials and Methods
Between 2009 and 2017, non-small cell lung cancer (NSCLC) patients who showed an exon 20 insertion were retrospectively reviewed for clinical characteristics and outcomes, including responses to chemotherapy (CTx) or targeted therapy.
Results
Of 3,539 NSCLC patients who harbored an activating EGFR mutation, 56 (1.6%) had an exon 20 insertion. Of the advanced NSCLC patients, 27 of 1,479 (1.8%) had an exon 20 insertion. The median overall survival was 29.4 months (95% confidence interval 9.3 to 49.6) for 27 advancedNSCLC patients. The 22 patientswho received systemic CTx achieved a 50.0% response rate and a 77.2% disease control rate, with 4.2 months of progressionfree survival. Six patients received EGFR tyrosine kinase inhibitors (TKIs). Three of the four patients that had only an exon 20 insertion showed progressive disease, while one showed stable disease. The othertwo patients had an exon 20 insertion and another EGFR mutation and achieved a partial response.
Conclusion
The incidence of an exon 20 insertion mutation is rare in Korea and occasionally accompanied by other common EGFR mutations. Although the response to systemic CTx. in these patients is comparable to that of patients with other mutations, the response rate to firstor second-generation EGFR TKIs is quite low. Therefore, the development of a more efficient agent is urgently needed.

Citations

Citations to this article as recorded by  
  • First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
    Pasi A. Jänne, Bin-Chao Wang, Byoung Chul Cho, Jun Zhao, Juan Li, Maximilian Hochmair, Solange Peters, Benjamin Besse, Nick Pavlakis, Joel W. Neal, Terufumi Kato, Yi-Long Wu, Danny Nguyen, Junjing Lin, Jianchang Lin, Florin Vranceanu, Annette Szumski, Hua
    Journal of Clinical Oncology.2025;[Epub]     CrossRef
  • The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of EGFR exon 20: A retrospective analysis
    Ke-Jun Liu, Hong-Rui Li, Quan-Quan Tan, Tao Jiang, Kai-Cheng Peng, Hua-Jun Chen, Qing Zhou, Xu-Chao Zhang, Zheng Zheng, Shi-Yuan Chen, Xue Zheng, Hong-Bo Zheng, Bei-Bei Mao, Long-Long Gong, Xian-Wen Chen, Wendy Wu, Yi-Long Wu, Jun Jia, Jin-Ji Yang
    Science Progress.2025;[Epub]     CrossRef
  • Advances in the Diagnosis and Treatment of Advanced Non–Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
    Jingwen Liu, Yan Xiang, Tingwen Fang, Lulin Zeng, Ao Sun, Yixiang Lin, Kaihua Lu
    Clinical Lung Cancer.2024; 25(2): 100.     CrossRef
  • Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
    Maximilian J. Hochmair, Mojca Unk, Jelena Spasic, Timur Cerić, Assia Konsoulova, Mircea Dediu, Krisztina Bogos, Alinta Hegmane, Kersti Oselin, Marko Stojiljkovic, Tina Roblek, Marko Jakopovic
    BMC Proceedings.2024;[Epub]     CrossRef
  • Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia
    Masanobu Okahisa, Hibiki Udagawa, Shingo Matsumoto, Terufumi Kato, Hiroshi Yokouchi, Naoki Furuya, Ryota Kanemaru, Ryo Toyozawa, Akihiro Nishiyama, Kadoaki Ohashi, Shingo Miyamoto, Kazumi Nishino, Atsushi Nakamura, Eiji Iwama, Seiji Niho, Hajime Oi, Tetsu
    Lung Cancer.2024; 191: 107798.     CrossRef
  • The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation
    Xiuyue Man, Xueru Sun, Chen Chen, Yan Xiang, Jing Zhang, Lei Yang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
    Pınar Gursoy, Ali Murat Tatli, Dilek Erdem, Erdem Goker, Emir Celik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atci, Ertuğrul Bayram, Tuğba Akın Telli, Burak Bilgin, Ahmet Bilici, Baran Akangunduz, Sevinç Balli, Ahmet Demirkazik, Fatih Selçukb
    Journal of Cancer Research and Clinical Oncology.2023; 149(2): 865.     CrossRef
  • Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison
    Sai-Hong I. Ou, Huamao M. Lin, Jin-Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Pingkuan Zhang, Danny Nguyen, Joel W. Neal
    Lung Cancer.2023; 179: 107186.     CrossRef
  • EGFR and ERBB2 exon 20 insertion/duplication in advanced non–small cell lung cancer: genomic profiling and clinicopathologic features
    Ramakrishna R. Sompallae, Bilge Dundar, Natalya V. Guseva, Aaron D. Bossler, Deqin Ma
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions
    Ying-Ting Liao, Lei-Chi Wang, Ruei-Lin Sun, Yi-Chen Yeh, Hsu-Ching Huang, Chia-I Shen, Yen-Han Tseng, Tsu-Hui Hsiao, Heng-Sheng Chao, Yung-Hung Luo, Yuh-Min Chen, Chi-Lu Chiang
    Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10365.     CrossRef
  • EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies
    Qianming Bai, Jialei Wang, Xiaoyan Zhou
    Cancer Treatment Reviews.2023; 120: 102605.     CrossRef
  • A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments
    Fenneke Zwierenga, Bianca A.M.H. van Veggel, Anke van den Berg, Harry J.M. Groen, Lili Zhang, Matthew R. Groves, K. Kok, E.F. Smit, T. Jeroen N. Hiltermann, Adrianus J. de Langen, Anthonie J. van der Wekken
    Cancer Treatment Reviews.2023; 120: 102628.     CrossRef
  • Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer
    Binyang Pan, Jiaqi Liang, Haochun Shi, Kungeng Rao, Weigang Guo, Cheng Zhan
    Thoracic Cancer.2023; 14(33): 3247.     CrossRef
  • Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report
    Youjun Deng, Chenglin Yang, Wenyi Liu, Songhua Cai, Xiaotong Guo
    Anti-Cancer Drugs.2022; 33(4): 406.     CrossRef
  • Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer
    Neeraj Gupta, Philippe B. Pierrillas, Michael J. Hanley, Steven Zhang, Paul M. Diderichsen
    CPT: Pharmacometrics & Systems Pharmacology.2022; 11(6): 731.     CrossRef
  • Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
    Timothée Olivier, Vinay Prasad
    Translational Oncology.2022; 23: 101475.     CrossRef
  • Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
    Yasir Y. Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Hai Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiuning Le, Marcelo V. Negrao, Monique B. Nilsson, Anisha Patel, R.S.K. Vijayan, Jason B. Cross, Jianjun Zhan
    Cancer Cell.2022; 40(7): 754.     CrossRef
  • EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors
    Guangjian Yang, Yaning Yang, Jiaqi Hu, Haiyan Xu, Shuyang Zhang, Yan Wang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis
    Ainur F. Nasretdinov, Konstantin V. Menshikov, Alexander V. Sultanbaev, Shamil I. Musin, Nadezda I. Sultanbaeva, Irina A. Men'shikova
    Journal of Modern Oncology.2022; 24(3): 340.     CrossRef
  • Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
    Maria Garcia Campelo, Caicun Zhou, Suresh Ramalingam, Huamao Lin, Tae Kim, Gregory Riely, Tarek Mekhail, Danny Nguyen, Erin Goodman, Minal Mehta, Sanjay Popat, Pasi Jänne
    Journal of Clinical Medicine.2022; 12(1): 112.     CrossRef
  • Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations
    Guang-Jian Yang, Jun Li, Hai-Yan Xu, Yang Sun, Liu Liu, Hong-Shuai Li, Lu Yang, Yuan Zhang, Guo-Hui Li, Yan Wang
    Lung Cancer.2021; 152: 39.     CrossRef
  • Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review
    Heather Burnett, Helena Emich, Chris Carroll, Naomi Stapleton, Parthiv Mahadevia, Tracy Li, Rama Krishna Kancha
    PLOS ONE.2021; 16(3): e0247620.     CrossRef
  • Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions
    Noura J. Choudhury, Adam J. Schoenfeld, Jessica Flynn, Christina J. Falcon, Hira Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena A. Yu, Marc Ladanyi, Gregory J. Riely
    Clinical Cancer Research.2021; 27(10): 2920.     CrossRef
  • EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer
    Jose Luis Leal, Marliese Alexander, Malinda Itchins, Gavin M. Wright, Steven Kao, Brett G.M. Hughes, Nick Pavlakis, Stephen Clarke, Anthony J Gill, Hannah Ainsworth, Benjamin Solomon, Thomas John
    Clinical Lung Cancer.2021; 22(6): e859.     CrossRef
  • Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
    Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira, Zofia Piotrowska, Daniel B. Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazhenova, Viola W. Zhu, Howard L. West, Tarek Mekhail, Ryan D. Gentzler, Danny Nguyen, Sylv
    Cancer Discovery.2021; 11(7): 1688.     CrossRef
  • Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
    Chie Morita, Tatsuya Yoshida, Masayuki Shirasawa, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Shigehiro Yagishita, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Noriko Motoi, Yasushi Yatabe, Yuichiro Ohe
    Scientific Reports.2021;[Epub]     CrossRef
  • EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
    Samy Chelabi, Xavier Mignard, Karen Leroy, Isabelle Monnet, Solenn Brosseau, Nathalie Theou-Anton, Marie-Ange Massiani, Sylvie Friard, Boris Duchemann, Elizabeth Fabre, Etienne Giroux-Leprieur, Jacques Cadranel, Marie Wislez
    Cancers.2021; 13(20): 5132.     CrossRef
  • Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
    Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim, Sang-We Kim, James Chih-Hsin Yang, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, Maria R. Garcia Campelo, Enriqueta Felip, Sylvie Vincent, Shu Jin, Celina Griffin, Veronica Bunn, Jianchang Lin, Huamao M. Li
    JAMA Oncology.2021; 7(12): e214761.     CrossRef
  • A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
    Christos Chouaid, Thomas Filleron, Didier Debieuvre, Maurice Pérol, Nicolas Girard, Eric Dansin, Hervé Lena, Radj Gervais, Sophie Cousin, Josiane Otto, Roland Schott, David Planchard, Anne Madroszyk, Courèche Kaderbhai, Pascale DUBRAY-Longeras, Sandrine H
    Targeted Oncology.2021; 16(6): 801.     CrossRef
  • External Quality Assurance of Current Technology for the Testing of Cancer-Associated Circulating Free DNA Variants
    Sze Yee Chai, Rongxue Peng, Rui Zhang, Li Zhou, Nalishia Pillay, Kwang Hong Tay, Tony Badrick, Jinming Li, Martin P. Horan
    Pathology & Oncology Research.2020; 26(3): 1595.     CrossRef
  • Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
    B. van Veggel, J.F. Vilacha Madeira R Santos, S.M.S. Hashemi, M.S. Paats, K. Monkhorst, D.A.M. Heideman, M. Groves, T. Radonic, E.F. Smit, E. Schuuring, A.J. van der Wekken, A.J. de Langen
    Lung Cancer.2020; 141: 9.     CrossRef
  • EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study
    Guangjian Yang, Jun Li, Haiyan Xu, Yaning Yang, Lu Yang, Fei Xu, Bing Xia, Viola W. Zhu, Misako Nagasaka, Yan Yang, Yapin Li, Weini Qiu, Jianming Ying, Sai-Hong Ignatius Ou, Yan Wang
    Lung Cancer.2020; 145: 186.     CrossRef
  • Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
    YanRu Qin, Hong Jian, Xiaoling Tong, Xue Wu, Fufeng Wang, Yang W. Shao, Xinmin Zhao
    Molecular Oncology.2020; 14(8): 1695.     CrossRef
  • The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
    Shang-Gin Wu, Chong-Jen Yu, James Chih-Hsin Yang, Jin-Yuan Shih
    Therapeutic Advances in Medical Oncology.2020;[Epub]     CrossRef
  • Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India
    Varsha Singh, Aruna Nambirajan, Prabhat Singh Malik, Sanjay Thulkar, Ravindra Mohan Pandey, Kalpana Luthra, Sudheer Arava, Ruma Ray, Anant Mohan, Deepali Jain
    Lung Cancer.2020; 149: 53.     CrossRef
  • Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations
    Jenn-Yu Wu, Chong-Jen Yu, Jin-Yuan Shih
    Clinical Lung Cancer.2019; 20(6): e620.     CrossRef
  • Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
    J. Chantharasamee, N. Poungvarin, P. Danchaivijitr, S. Techawatanawanna
    BMC Cancer.2019;[Epub]     CrossRef
  • Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
    Ya Gao, Wies R. Vallentgoed, Pim J. French
    Cancers.2018; 10(12): 489.     CrossRef
  • 16,474 View
  • 705 Download
  • 44 Web of Science
  • 38 Crossref
Close layer
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
Song Ee Park, Jae Myoung Noh, You Jin Kim, Han Sang Lee, Jang Ho Cho, Sung Won Lim, Yong Chan Ahn, Hongryull Pyo, Yoon-La Choi, Joungho Han, Jong-Mu Sun, Se Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):493-501.   Published online June 18, 2018
DOI: https://doi.org/10.4143/crt.2018.125
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to evaluate the relationship between epidermal growth factor receptor (EGFR) mutation and clinical outcomes in patients with stage III non-squamous cell lung cancer treated with definitive concurrent chemoradiotherapy (CCRT).
Materials and Methods
From January 2008 to December 2013, the medical records of 197 patients with stage III non- squamous non-small cell lung cancer treated with definitive CCRT were analyzed to determine progression-free survival (PFS) and overall survival (OS) according to EGFR mutation status.
Results
Among 197 eligible patients, 81 patients were EGFR wild type, 36 patients had an EGFR mutation (exon 19 Del, n=18; L858R, n=9, uncommon [G719X, L868, T790M], n=9), and 80 patients had unknown EGFR status. The median age was 59 years (range, 28 to 80 years) and 136 patients (69.0%) were male. The median follow-up duration was 66.5 months (range, 1.9 to 114.5 months). One hundred sixty-four patients (83.2%) experienced disease progression. Median PFS was 8.9 months for the EGFR mutation group, 11.8 months for EGFR wild type, and 10.5 months for the unknown EGFR group (p=0.013 and p=0.042, respectively). The most common site of metastasis in the EGFR mutant group was the brain. However, there was no significant difference in OS among the three groups (34.6 months for EGFR mutant group vs. 31.9 months for EGFR wild type vs. 22.6 months for EGFR unknown group; p=0.792 and p=0.284). A total of 29 patients (80.6%) with EGFR mutation were treated with EGFR tyrosine kinase inhibitor (gefitinib, n=24; erlotinib, n=3; afatinib, n=2) upon progression.
Conclusion
EGFR mutation is associatedwith short PFS and the brain is the most common site of distant metastasis in patients with stage III non- squamous cell lung cancer treated with CCRT.

Citations

Citations to this article as recorded by  
  • Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
    Terufumi Kato, Ignacio Casarini, Manuel Cobo, Corinne Faivre-Finn, Fiona Hegi-Johnson, Shun Lu, Mustafa Özgüroğlu, Suresh S. Ramalingam
    Lung Cancer.2024; 187: 107414.     CrossRef
  • Treatment patterns and survival analysis in patients with unresectable stage III EGFR-mutated non-small cell lung cancer
    Huan-Wei Liang, Yang Liu, Xin-Bin Pan
    Aging.2024;[Epub]     CrossRef
  • Durvalumab after chemoradiotherapy in non‐small cell lung cancer with EGFR mutation: A real‐world study (HOT2101)
    Kosuke Tsuji, Hidenori Mizugaki, Keiki Yokoo, Maki Kobayashi, Yosuke Kawashima, Nozomu Kimura, Hiroshi Yokouchi, Hajime Kikuchi, Toshiyuki Sumi, Yasutaka Kawai, Kenta Kobashi, Ryo Morita, Kenichiro Ito, Yasuo Kitamura, Hiroyuki Minemura, Keiichi Nakamura,
    Cancer Science.2024; 115(4): 1273.     CrossRef
  • Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
    Amin H. Nassar, So Yeon Kim, Jacqueline V. Aredo, Jamie Feng, Frances Shepherd, Chao Xu, David Kaldas, Jhanelle E. Gray, Thomas J. Dilling, Joel W. Neal, Heather A. Wakelee, Yufei Liu, Steven H. Lin, Tariq Abuali, Arya Amini, Yunan Nie, Tejas Patil, Anast
    Journal of Thoracic Oncology.2024; 19(6): 928.     CrossRef
  • Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers
    David J. Stewart, Katherine Cole, Dominick Bosse, Stephanie Brule, Dean Fergusson, Tim Ramsay
    Current Oncology.2024; 31(3): 1600.     CrossRef
  • Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
    Shun Lu, Terufumi Kato, Xiaorong Dong, Myung-Ju Ahn, Le-Van Quang, Nopadol Soparattanapaisarn, Takako Inoue, Chih-Liang Wang, Meijuan Huang, James Chih-Hsin Yang, Manuel Cobo, Mustafa Özgüroğlu, Ignacio Casarini, Dang-Van Khiem, Virote Sriuranpong, Eduard
    New England Journal of Medicine.2024; 391(7): 585.     CrossRef
  • Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
    S. Lu, M.-J. Ahn, T. Reungwetwattana, M. Özgüroğlu, T. Kato, J.C.-H. Yang, M. Huang, F. Fujiki, T. Inoue, L.-V. Quang, V. Sriuranpong, D. Vicente, C. Fuentes, A.A. Chaudhry, L. Poole, E. Armenteros Monterroso, Y. Rukazenkov, T. van der Gronde, S.S. Ramali
    Annals of Oncology.2024; 35(12): 1116.     CrossRef
  • Comparison of treatment regimens for unresectable stage III epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer
    Xin Dai, Qian Xu, Lei Sheng, Xue Zhang, Miao Huang, Song Li, Kai Huang, Jiahui Chu, Jian Wang, Jisheng Li, Yanguo Liu, Jianyuan Zhou, Shulun Nie, Lian Liu
    Chinese Medical Journal.2024;[Epub]     CrossRef
  • Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy
    Jaewon Hyung, Hyunseok Yoon, Chang-Min Choi, Shinkyo Yoon, Dae Ho Lee, Sang-we Kim, Hyeong-ryul Kim, Su Ssan Kim, Si Yeol Song, Jae Cheol Lee
    Journal of Cancer Research and Clinical Oncology.2023; 149(8): 4243.     CrossRef
  • Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: A multi-center cohort study
    Nan Bi, Kunpeng Xu, Hong Ge, Ming Chen, Mingyan E, Li Zhang, Jianzhong Cao, Xu Zhang, Xiao Ding, Bing Xia, Lujun Zhao, Lijie Han, Jiancheng Li, Chen Hu, Luhua Wang
    Journal of the National Cancer Center.2023; 3(1): 65.     CrossRef
  • Locally Advanced Lung Cancer
    Sarah Oh, George N. Botros, Milan Patel, Missak Haigentz, Eshan Patel, Iaonnis Kontopidis, John Langenfeld, Matthew P. Deek, Salma K. Jabbour
    Hematology/Oncology Clinics of North America.2023; 37(3): 533.     CrossRef
  • Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations
    Ling Zhang, Yunhong You, Xueli Liu, Fengjuan Liu, Keke Nie, Youxin Ji
    Thoracic Cancer.2023; 14(15): 1355.     CrossRef
  • EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis
    Hongsik Kim, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn
    Cancer Research and Treatment.2023; 55(2): 498.     CrossRef
  • Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients
    Yang Liu, Huan-Wei Liang, Xin-Bin Pan
    Aging.2023;[Epub]     CrossRef
  • Improved survival in patients with unresectable stage III EGFR‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
    Sheng‐Yuan Wang, Ching‐Han Lai, Chian‐Wei Chen, Szu‐Chun Yang, Chao‐Chun Chang, Chia‐Ying Lin, Yi‐Ting Yen, Yau‐Lin Tseng, Po‐Lan Su, Chien‐Chung Lin, Wu‐Chou Su
    Thoracic Cancer.2022; 13(2): 182.     CrossRef
  • Nuclear accumulation of KPNA2 impacts radioresistance through positive regulation of the PLSCR1‐STAT1 loop in lung adenocarcinoma
    Wei‐Chao Liao, Tsung‐Jen Lin, Yu‐Chin Liu, Yu‐Shan Wei, Guan‐Ying Chen, Hsiang‐Pu Feng, Yi‐Feng Chang, Hsin‐Tzu Chang, Chih‐Liang Wang, Hsinag‐Cheng Chi, Chun‐I Wang, Kwang‐Huei Lin, Wei‐Ting Ou Yang, Chia‐Jung Yu
    Cancer Science.2022; 113(1): 205.     CrossRef
  • An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
    Po-Lan Su, Gee-Chen Chang, Shih-Hsin Hsiao, Te-Chun Hsia, Meng-Chih Lin, Min-Hsi Lin, Jin-Yuan Shih, Cheng-Ta Yang, Sheng-Hsiung Yang, Yuh-Min Chen
    JTO Clinical and Research Reports.2022; 3(3): 100292.     CrossRef
  • Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study
    Yuxiang Wang, Wenjuan Yu, Jian Shi, Rong Qiu, Nan Jiang, Zhuofan Wang, Jie Yang, Zhongfei Jia, Meng Song
    Technology in Cancer Research & Treatment.2022;[Epub]     CrossRef
  • Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)
    Luis E. Raez, Oscar Arrieta, Diego F. Chamorro, Pamela Denisse Soberanis-Piña, Luis Corrales, Claudio Martín, Mauricio Cuello, Suraj Samtani, Gonzalo Recondo, Luis Mas, Zyanya Lucia Zatarain-Barrón, Alejandro Ruíz-Patiño, Juan Esteban García-Robledo, Cami
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion
    Yoonki Hong, Sunmin Park, Myoung Kyu Lee
    Scientific Reports.2022;[Epub]     CrossRef
  • First results of durvalumab after chemoradiotherapy in locally advanced non-small-cell lung cancer in Russia
    D. I. Yudin, K. K. Laktionov, F. V. Moiseenko, D. M. Ponomarenko, E. A. Chekh, V. A. Chubenko, N. V. Levchenko, V. V. Kozlov, E. О. Stepanova, K. A. Sarantseva, E. S. Denisova, M. S. Ardzinba, D. Yu. Yukalchuk
    Meditsinskiy sovet = Medical Council.2022; (22): 12.     CrossRef
  • Clinical outcomes and radiation pneumonitis after concurrent EGFR‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer
    Kunpeng Xu, Jun Liang, Tao Zhang, Zongmei Zhou, Dongfu Chen, Qinfu Feng, Zefen Xiao, Zhouguang Hui, Jima Lu, Xin Wang, Lei Deng, Wenyang Liu, Jianyang Wang, Yirui Zhai, Jie Wang, Nan Bi, Luhua Wang
    Thoracic Cancer.2021; 12(6): 814.     CrossRef
  • Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
    Jacqueline V. Aredo, Isa Mambetsariev, Jessica A. Hellyer, Arya Amini, Joel W. Neal, Sukhmani K. Padda, Caroline E. McCoach, Jonathan W. Riess, Elwyn C. Cabebe, Jarushka Naidoo, Tariq Abuali, Ravi Salgia, Billy W. Loo, Maximilian Diehn, Summer S. Han, Hea
    Journal of Thoracic Oncology.2021; 16(6): 1030.     CrossRef
  • Einfluss der Molekularpathologie auf die onkologische Chirurgie von Leber- und Gallengangstumoren
    Mazen A. Juratli, Benjamin Struecker, Shadi Katou, M. Haluk Morguel, Andreas Pascher
    Der Chirurg.2021; 92(11): 1003.     CrossRef
  • Locally Advanced, Unresectable Non-Small Cell Lung Cancer
    Sonam Puri, Andreas Saltos, Bradford Perez, Xiuning Le, Jhanelle E. Gray
    Current Oncology Reports.2020;[Epub]     CrossRef
  • Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
    Hyun Ae Jung, Jae Myoung Noh, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Hongryull Pyo, Yong Chan Ahn, Keunchil Park
    Lung Cancer.2020; 146: 23.     CrossRef
  • Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
    Connor O’Leary, Harry Gasper, Katherine B. Sahin, Ming Tang, Arutha Kulasinghe, Mark N. Adams, Derek J. Richard, Ken J. O’Byrne
    Pharmaceuticals.2020; 13(10): 273.     CrossRef
  • MiRNAs: A New Approach to Predict and Overcome Resistance to Anticancer Drugs
    Noor Altaleb
    Clinical Cancer Drugs.2020; 7(2): 65.     CrossRef
  • Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations
    Bumhee Yang, Hyun Lee, Sang-Won Um, Kyunga Kim, Jae Il Zo, Young Mog Shim, O Jung Kwon, Kyung Soo Lee, Myung-Ju Ahn, Hojoong Kim
    Lung Cancer.2019; 129: 28.     CrossRef
  • A Prediction Rule for Overall Survival in Non-Small-Cell Lung Cancer Patients with a Pathological Tumor Size Less Than 30 mm
    Wang-Yu Zhu, Ke-xin Fang, Jian-ying He, Ri Cui, Yong-Kui Zhang, Han-bo Le
    Disease Markers.2019; 2019: 1.     CrossRef
  • 13,327 View
  • 471 Download
  • 29 Web of Science
  • 30 Crossref
Close layer
Erratum
ERRATUM: Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor
Jang Ho Cho, Jae Yun Lim, Ah Ran Choi, Sung Min Choi, Jong Won Kim, Seung Ho Choi, Jae Yong Cho
Cancer Res Treat. 2018;50(1):302-302.   Published online December 6, 2017
DOI: https://doi.org/10.4143/crt.2013.175.2
Corrects: Cancer Res Treat 2015;47(4):697
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • A Case Report of Secondary Ovarian Malignant Tumor and Literature Study
    曦 陈
    Advances in Clinical Medicine.2025; 15(02): 1086.     CrossRef
  • 6,689 View
  • 210 Download
  • 2 Web of Science
  • 1 Crossref
Close layer
Original Articles
Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor
Jang Ho Cho, Jae Yun Lim, Ah Ran Choi, Sung Min Choi, Jong Won Kim, Seung Ho Choi, Jae Yong Cho
Cancer Res Treat. 2015;47(4):697-705.   Published online November 27, 2014
DOI: https://doi.org/10.4143/crt.2013.175
Correction in: Cancer Res Treat 2018;50(1):302
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to validate the survival benefit of metastasectomy plus chemotherapy over chemotherapy alone for treatment of Krukenberg tumors from gastric cancer and to identify prognostic factors for survival. Materials and Methods Clinical data from 216 patients with Krukenberg tumors from gastric cancer were collected. Patients were divided into two arms according to treatment modality: arm A, metastasectomy plus chemotherapy and arm B, chemotherapy alone. Results Overall survival (OS) was significantly increased in arm A relative to arm B for patients initially diagnosed with stage IV gastric cancer (18.0 months vs. 8.0 months; p < 0.001) and those with recurrent Krukenberg tumors (19.0 months vs. 9.0 months; p=0.002), respectively. Metastasectomy (hazard ratio [HR], 0.458; 95% confidence interval [CI], 0.287 to 0.732; p=0.001), signet-ring cell pathology (HR, 1.583; 95% CI, 1.057 to 2.371; p=0.026), and peritoneal carcinomatosis (HR, 3.081; 95% CI, 1.610 to 5.895; p=0.001) were significant prognostic factors for survival. Conclusion Metastasectomy plus chemotherapy offers superior OS when compared to palliative chemotherapy alone in gastric cancer with Krukenberg tumor. Prolonged survival applies to all patients, regardless of gastric cancer stage. Metastasectomy, signet-ring cell pathology, and peritoneal carcinomatosis were prognostic factors for survival. Future prospective randomized trials are needed to confirm the optimal treatment strategy for Krukenberg tumors from gastric cancer.

Citations

Citations to this article as recorded by  
  • Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)
    In-Ho Kim, Seung Joo Kang, Wonyoung Choi, An Na Seo, Bang Wool Eom, Beodeul Kang, Bum Jun Kim, Byung-Hoon Min, Chung Hyun Tae, Chang In Choi, Choong-kun Lee, Ho Jung An, Hwa Kyung Byun, Hyeon-Su Im, Hyung-Don Kim, Jang Ho Cho, Kyoungjune Pak, Jae-Joon Kim
    Journal of Gastric Cancer.2025; 25(1): 5.     CrossRef
  • Combined treatment of patients with ovarian metastases from gastrointestinal cancer
    N. Yu. Sokolov, Z. A. Bagatelia, D. N. Grekov, I. A. Polyakov, V. M. Kulushеv, V. A. Alimov, K. S. Titov, S. S. Lebedev, A. K. Chekini, I. O. Tinkova, N. M. Podzolkova
    Surgery and Oncology.2025; 15(1): 42.     CrossRef
  • The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
    Feng‐Hua Wang, Xiao‐Tian Zhang, Lei Tang, Qi Wu, Mu‐Yan Cai, Yuan‐Fang Li, Xiu‐Juan Qu, Hong Qiu, Yu‐Jing Zhang, Jie‐Er Ying, Jun Zhang, Ling‐Yu Sun, Rong‐Bo Lin, Chang Wang, Hao Liu, Miao‐Zhen Qiu, Wen‐Long Guan, Sheng‐Xiang Rao, Jia‐Fu Ji, Yan Xin, Wei‐
    Cancer Communications.2024; 44(1): 127.     CrossRef
  • Oligometastasis of Gastric Cancer: A Review
    Itaru Yasufuku, Hiroshi Tsuchiya, Seito Fujibayashi, Naoki Okumura, Yuki Sengoku, Masahiro Fukada, Ryuichi Asai, Yuta Sato, Jesse Yu Tajima, Shigeru Kiyama, Takazumi Kato, Yoshihiro Tanaka, Katsutoshi Murase, Nobuhisa Matsuhashi
    Cancers.2024; 16(3): 673.     CrossRef
  • Colorectal Origin: A Marker of Favorable Outcome in Krukenberg Tumor? Results from Clinical and Prognostic Analysis
    Purnima Thakur, Mukesh Sharma, Ashish Chauhan, Kapil M. Pal, Shabnam Thakur, Manish Gupta, Shilpa Kaushal
    South Asian Journal of Cancer.2024; 13(02): 099.     CrossRef
  • Surgical resection and neoadjuvant therapy in patients with gastric cancer and ovarian metastasis: A real-world study
    Hui-Ping Yan, Hong-Rui Lu, Yu-Xia Zhang, Liu Yang, Zhe-Ling Chen
    World Journal of Gastrointestinal Surgery.2024; 16(8): 2426.     CrossRef
  • MRI characteristics of ovarian metastasis: differentiation from stomach and colorectal cancer
    Yukiko Takai, Hiroki Kato, Masaya Kawaguchi, Kazuhiro Kobayashi, Kyoko Kikuno, Tatsuro Furui, Masanori Isobe, Yoshifumi Noda, Fuminori Hyodo, Masayuki Matsuo
    Japanese Journal of Radiology.2024;[Epub]     CrossRef
  • The four cases of metastatic ovarian tumor treated with laparoscopic bilateral salpingo-oophorectomy
    Akira Kawata, Mayuko Goda, Ryo Koike, Hirofumi Inaba, Fumi Misumi, Sho Mizuno, Yurina Suzuki, Koji Horie
    JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY.2024; 40(2): 175.     CrossRef
  • Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
    Tae-Han Kim, In-Ho Kim, Seung Joo Kang, Miyoung Choi, Baek-Hui Kim, Bang Wool Eom, Bum Jun Kim, Byung-Hoon Min, Chang In Choi, Cheol Min Shin, Chung Hyun Tae, Chung sik Gong, Dong Jin Kim, Arthur Eung-Hyuck Cho, Eun Jeong Gong, Geum Jong Song, Hyeon-Su Im
    Journal of Gastric Cancer.2023; 23(1): 3.     CrossRef
  • Efficacy of chemotherapy combined with surgical resection for gastric cancer with synchronous ovarian metastasis: A propensity score matching analysis
    Jingquan Fang, Xingmao Huang, Xiangliu Chen, Qi Xu, Tengjiao Chai, Ling Huang, Han Chen, Hang Chen, Zeyao Ye, Yian Du, Pengfei Yu
    Cancer Medicine.2023; 12(16): 17126.     CrossRef
  • Clinical Features of Gastric Signet Ring Cell Cancer: Results from a Systematic Review and Meta-Analysis
    Mariagiulia Dal Cero, Maria Bencivenga, Drolaiz H. W. Liu, Michele Sacco, Mariella Alloggio, Kelly G. P. Kerckhoffs, Federica Filippini, Luca Saragoni, Mar Iglesias, Anna Tomezzoli, Fátima Carneiro, Heike I. Grabsch, Giuseppe Verlato, Lorena Torroni, Guil
    Cancers.2023; 15(21): 5191.     CrossRef
  • Frequency and therapeutic strategy for patients with ovarian metastasis from gastric cancer
    Tsutomu Namikawa, Akira Marui, Keiichiro Yokota, Yasuhiro Kawanishi, Masaya Munekage, Sunao Uemura, Hiromichi Maeda, Hiroyuki Kitagawa, Michiya Kobayashi, Kazuhiro Hanazaki
    Langenbeck's Archives of Surgery.2022; 407(6): 2301.     CrossRef
  • Clinics and pathology of Krukenberg tumor: a systematic review and meta-analysis
    Ruggero LIONETTI, Marcello DE LUCA, Antonio RAFFONE, Antonio TRAVAGLINO, Alberto COPPELLOTTI, Roberto PELTRINI, Umberto BRACALE, Michele D’AMBRA, Luigi INSABATO, Fulvio ZULLO, Maria D’ARMIENTO, Francesco CORCIONE
    Minerva Obstetrics and Gynecology.2022;[Epub]     CrossRef
  • Seventeen-year Survival of a Case of Advanced Gastric Cancer with Krukenberg Tumor Treated by Oophorectomies, Subsequent Gastrectomy, and Chemotherapy
    Yoshiro NISHIWAKI, Hideto OCHIAI, Toshikazu KANAI, Hiroaki TAMURA, Tadataka HAYASHI, Shinichiro MIYAZAKI, Shinichi HASEGAWA, Takeshi BABA
    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2022; 83(4): 675.     CrossRef
  • Gastric linitis plastica due to signet-ring cell carcinoma with Krukenberg tumors diagnosed by endoscopic ultrasound-guided fine-needle aspiration
    Takeshi Okamoto, Hidekazu Suzuki, Katsuyuki Fukuda
    Clinical Journal of Gastroenterology.2021; 14(4): 994.     CrossRef
  • The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
    Feng‐Hua Wang, Xiao‐Tian Zhang, Yuan‐Fang Li, Lei Tang, Xiu‐Juan Qu, Jie‐Er Ying, Jun Zhang, Ling‐Yu Sun, Rong‐Bo Lin, Hong Qiu, Chang Wang, Miao‐Zhen Qiu, Mu‐Yan Cai, Qi Wu, Hao Liu, Wen‐Long Guan, Ai‐Ping Zhou, Yu‐Jing Zhang, Tian‐Shu Liu, Feng Bi, Xian
    Cancer Communications.2021; 41(8): 747.     CrossRef
  • Is Routine Gastroscopy/Colonoscopy Reasonable in Patients With Suspected Ovarian Cancer: A Retrospective Study
    Guochen Liu, Junping Yan, Shanshan Long, Zhimin Liu, Haifeng Gu, Hua Tu, Jundong Li
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Surgical management of oligometastatic disease in gastric cancer
    Peng Jin, Xiaoyan Ji, Yantao Tian
    Clinics and Research in Hepatology and Gastroenterology.2020; 44(5): 638.     CrossRef
  • The role of surgical resection before palliative chemotherapy in advanced gastric cancer
    Yong Won Choi, Mi Sun Ahn, Geum Sook Jeong, Hyun Woo Lee, Seong Hyun Jeong, Seok Yun Kang, Joon Seong Park, Jin-Hyuk Choi, Sang-Yong Son, Hoon Hur, Sang-Uk Han, Seung Soo Sheen
    Scientific Reports.2019;[Epub]     CrossRef
  • The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer
    Feng‐Hua Wang, Lin Shen, Jin Li, Zhi‐Wei Zhou, Han Liang, Xiao‐Tian Zhang, Lei Tang, Yan Xin, Jing Jin, Yu‐Jing Zhang, Xiang‐Lin Yuan, Tian‐Shu Liu, Guo‐Xin Li, Qi Wu, Hui‐Mian Xu, Jia‐Fu Ji, Yuan‐Fang Li, Xin Wang, Shan Yu, Hao Liu, Wen‐Long Guan, Rui‐Hu
    Cancer Communications.2019; 39(1): 1.     CrossRef
  • Treatments and overall survival in patients with Krukenberg tumor
    Ruggero Lionetti, Marcello De Luca, Antonio Travaglino, Antonio Raffone, Luigi Insabato, Gabriele Saccone, Massimo Mascolo, Maria D’armiento, Fulvio Zullo, Francesco Corcione
    Archives of Gynecology and Obstetrics.2019; 300(1): 15.     CrossRef
  • Effects of metastasectomy and other factors on survival of patients with ovarian metastases from gastric cancer: a systematic review and meta‐analysis
    Chao Zhang, Wenbin Hou, Jinyu Huang, Songcheng Yin, Pengliang Wang, Zhe Zhang, Yuen Tan, Huimian Xu
    Journal of Cellular Biochemistry.2019; 120(9): 14486.     CrossRef
  • Multi-Modality Treatment for Patients With Metastatic Gastric Cancer: A Real-World Study in China
    Lin Zhao, Jiarui Li, Chunmei Bai, Yongdu Nie, Guole Lin
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Prognostic factors in Krukenberg tumor
    Ruggero Lionetti, Marcello De Luca, Antonio Travaglino, Antonio Raffone, Gabriele Saccone, Antonietta Di Cicco, Luigi Insabato, Massimo Mascolo, Maria D’Armiento, Fulvio Zullo, Francesco Corcione
    Archives of Gynecology and Obstetrics.2019; 300(5): 1155.     CrossRef
  • Palliative surgery for Krukenberg tumors – 12-year experience and review of the literature
    Isaac Seow-En, Gwen Hwarng, Grace Hwei Ching Tan, Leonard Ming Li Ho, Melissa Ching Ching Teo
    World Journal of Clinical Oncology.2018; 9(1): 13.     CrossRef
  • Pressurized intraperitoneal aerosol chemotheprapy after misdiagnosed gastric cancer: Case report and review of the literature
    Maciej Nowacki, Dariusz Grzanka, Wojciech Zegarski
    World Journal of Gastroenterology.2018; 24(19): 2130.     CrossRef
  • Is a Surgical Approach Justified in Metachronous Krukenberg Tumor from Gastric Cancer? A Systematic Review
    Paolo Aurello, Giammauro Berardi, Laura Antolino, Giulio Antonelli, Alessia Rampini, Giovanni Moschetta, Giovanni Ramacciato
    Oncology Research and Treatment.2018; 41(10): 644.     CrossRef
  • An Unusual Cause of Acute Perforation
    Najib Nassani, Liliane Deeb, Sherif Andrawes
    Gastroenterology.2017; 152(5): 956.     CrossRef
  • Krukenberg tumors: Seed, route and soil
    Annamaria Agnes, Alberto Biondi, Riccardo Ricci, Valerio Gallotta, Domenico D'Ugo, Roberto Persiani
    Surgical Oncology.2017; 26(4): 438.     CrossRef
  • Comparison of a Panel of Biomarkers Between Gastric Primary Cancer and the Paired Krukenberg Tumor
    Bo Wang, Ke Sun, Yinying Zou
    Applied Immunohistochemistry & Molecular Morphology.2017; 25(9): 639.     CrossRef
  • Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China
    Pengfei Yu, Ling Huang, Guoping Cheng, Litao Yang, Gaiguo Dai, Jieer Ying, Yian Du
    Oncotarget.2017; 8(47): 82558.     CrossRef
  • Surgical treatment of gastric carcinoma with ovarian metastases
    Tomasz Olesinski
    Current Issues in Pharmacy and Medical Sciences.2017; 30(4): 195.     CrossRef
  • Krukenberg Tumors of Gastric Origin: The Rationale of Surgical Resection and Perioperative Treatments in a Multicenter Western Experience
    Fausto Rosa, Daniele Marrelli, Paolo Morgagni, Chiara Cipollari, Giovanni Vittimberga, Massimo Framarini, Luca Cozzaglio, Corrado Pedrazzani, Stefano Berardi, Gian Luca Baiocchi, Franco Roviello, Nazario Portolani, Giovanni de Manzoni, Guido Costamagna, G
    World Journal of Surgery.2016; 40(4): 921.     CrossRef
  • 21,731 View
  • 397 Download
  • 36 Web of Science
  • 33 Crossref
Close layer
Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
Jae Yun Lim, Jang Ho Cho, Se Joon Lee, Dong Ki Lee, Dong Sup Yoon, Jae Yong Cho
Cancer Res Treat. 2015;47(2):266-273.   Published online August 29, 2014
DOI: https://doi.org/10.4143/crt.2013.158
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to retrospectively compare the efficacy and tolerability between three regimens for first-line chemotherapy—gemcitabine plus capecitabine (GEM-X), gemcitabine plus erlotinib (GEM-T), and gemcitabine monotherapy (GEM)—in patients with advanced pancreatic cancer. Materials and Methods There was a total of 127 patients who underwent chemotherapy for pancreatic cancer between January 2007 and November 2011 at our institution. Patients were treated with either GEM (gemcitabine 1,000 mg/m2 on days 1, 8, and 15 every 4 weeks), GEM-T (gemcitabine 1,000 mg/m2 on days 1 and 8 every 3 weeks and erlotinib 100 mg daily), or GEM-X (gemcitabine 1,000 mg/m2 on days 1 and 8 every 3 weeks and capecitabine 850 mg/m2 twice daily for 2 weeks followed by 1 week’s rest) as the first-line treatment. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and toxicity were evaluated. Results The patient population was divided into groups depending on their first-line treatment: GEM (n=47), GEM-T (n=44), and GEM-X (n=36). GEM-X significantly improved ORR (21.2% vs. 12.7% and 15.9%), PFS (8.9 vs. 5.2 and 3.9 months; p < 0.001), and OS (12.1 vs. 10.4 and 9.9 months; p = 0.03) compared to GEM and GEM-T, respectively. There were higher incidences of some non-hematologic adverse events with GEM-X and GEM-T compared to GEM, but most were grade 1 or 2. Conclusion GEM-X presented better clinical efficacy and acceptable tolerability than GEM-T and GEM in advanced pancreatic cancers. It is worthy to further investigate which agent has a clinical advantage as a combination drug with gemcitabine in pancreatic cancer and to explore the predictive markers leading to personalize anti-cancer treatment.

Citations

Citations to this article as recorded by  
  • Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer: A meta-analysis
    Xiao-Yan Liu, Hong-Nian Pan, Yue Yu
    World Journal of Gastrointestinal Surgery.2024; 16(3): 921.     CrossRef
  • A Systematic Study of Novel Drug Delivery Mechanisms and Treatment Strategies for Pancreatic Cancer
    Umme Hani, Riyaz Ali M. Osmani, Ayesha Siddiqua, Shadma Wahab, Sadia Batool, Hissana Ather, Norhan Shereba, Ali Alqahtani
    Journal of Drug Delivery Science and Technology.2021; : 102539.     CrossRef
  • Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer
    Kunxi Bao, Xiaobing Li, Xiaojing He, Lingyan Jian
    Clinical Therapeutics.2021; 43(6): 1107.     CrossRef
  • Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?
    Lucie Jiraskova, Ales Ryska, Erik Jurjen Duintjer Tebbens, Helena Hornychova, Filip Cecka, Frantisek Staud, Lukas Cerveny
    Cancers.2019; 11(11): 1621.     CrossRef
  • Gemcitabine–erlotinib versus gemcitabine–erlotinib–capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group
    Antonio Irigoyen, Javier Gallego, Carmen Guillén Ponce, Ruth Vera, Vega Iranzo, Inmaculada Ales, Sara Arévalo, Aleydis Pisa, Marta Martín, Antonieta Salud, Esther Falcó, Alberto Sáenz, José Luis Manzano Mozo, Gema Pulido, Joaquina Martínez Galán, Roberto
    European Journal of Cancer.2017; 75: 73.     CrossRef
  • New targeted therapies in pancreatic cancer
    Andrada Seicean
    World Journal of Gastroenterology.2015; 21(20): 6127.     CrossRef
  • 14,304 View
  • 82 Download
  • 14 Web of Science
  • 6 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP